PSMA Conjugate Synthesis for Selective Prostate Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as hormonal therapy, radiation therapy, and chemotherapy, often cause significant side effects in patients, and there is a need for more selective and specific therapies targeting prostate-specific membrane antigen (PSMA) expressing cells to minimize harm to non-target tissues.
Innovation Solution
The development of conjugates that exhibit high affinity for PSMA, allowing for the delivery of diagnostic, imaging, and therapeutic agents to prostate cancer cells through processes involving resin-based compounds and specific chemical reactions with deprotecting agents, solvents, and coupling agents to prepare compounds like PSMA-617.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (hormonal therapy, radiation therapy, chemotherapy) are used to treat prostate cancer, then cancer cells can be targeted and treated, but significant side effects occur in non-target tissues such as bones and liver
Solution Approach 1:
The patent applies local quality by designing PSMA-targeting conjugates that concentrate therapeutic agents specifically at PSMA-expressing cancer cells. The conjugates contain PSMA-binding moieties that recognize and bind to PSMA receptors on prostate cancer cells, delivering cytotoxic agents locally to the tumor site while minimizing exposure to healthy tissues. This selective targeting resolves the contradiction by maintaining treatment efficacy while reducing harmful side effects in non-target organs.
Solution Approach 2:
The patent uses PSMA-binding conjugates as intermediaries to deliver therapeutic agents to cancer cells. These conjugates act as mediators that carry cytotoxic agents from the bloodstream to specific PSMA-expressing cells. The conjugate structure includes a PSMA-binding portion and a cytotoxic agent portion, creating an intermediary vehicle that enables selective delivery and reduces off-target effects while maintaining anti-cancer efficacy.
2Object-affected harmful factors
If PSMA-targeting conjugates are developed to improve selectivity, then side effects are reduced, but the complexity of the treatment approach increases
Solution Approach 1:
The patent applies universality by creating a modular conjugate platform that can deliver different cytotoxic agents through a common PSMA-binding structure. The conjugate design allows for interchangeable cytotoxic agents while maintaining the same PSMA-targeting mechanism. This multi-functional approach reduces complexity by standardizing the targeting portion while allowing flexibility in the therapeutic payload, making the overall approach more manageable despite the advanced targeting capability.
3Manufacturing precision
If high purity compounds are produced through multiple synthesis steps, then product quality is improved, but production time and cost increase
Solution Approach 1:
The patent applies preliminary action by incorporating protecting groups during the synthesis of PSMA-targeting conjugates. These protecting groups prevent unwanted side reactions during intermediate synthesis steps and are removed in a final deprotection step to yield the high-purity final product. This approach maintains manufacturing precision while reducing the number of intermediate purification steps needed, thereby improving overall production efficiency.
Solution Approach 2:
The patent implements continuity of useful action through solid-phase synthesis methods where reactions proceed continuously on resin beads. The conjugate synthesis occurs in a continuous manner with reagents flowing through the resin bed, allowing multiple reaction steps to occur in sequence without interrupting the useful action. This continuous process maintains high purity through inherent selectivity while improving productivity by eliminating repeated isolation and purification cycles.
Data Source
AI summary
This disclosure relates to processes for preparing compounds that are useful in the treatment of disease, such as cancer, in mammals. In particular, the invention described herein pertains to processes for preparing compounds capable of targeting PSMA expressing cells and useful in the treatment of diseases caused by PSMA expressing cells, such as prostate cancer.